Pediatric Municipal Hospital of Rzeszow, Poland Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2007
NCT01547910
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

College of Medical Sciences, University of Rzeszów | Medical University of Rzeszów

Active Ingredients

Drugs in Phase 4 Trials (2)

acetaminophen (tylenol) (1 trial)

oxycodone (oxycontin) (1 trial)

Drugs in Phase 3 Trials (1)

bacille calmette-guerin (1 trial)

Drugs in Phase 2 Trials (1)

fish oil (Omegavan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Coronavirus Infections (Phase 3)

Fatty Liver (Phase 2)

Infections (Phase 3)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pain, Postoperative (Phase 4)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4